Objectives: To evaluate whether the adjunct of an ultrasound contrast medium improves the detection rate of prostate cancer. Method: In 34 patients, scheduled to undergo a trans-perineal extended prostate biopsy, we carried out a color-Doppler ultrasound (CDU) of the prostate before and after i.v. injection of Levovist s , an ultrasound contrast medium. Further bioptic samples were taken in the areas where a marked increase in vascularization was noticed. Results: The overall diagnostic sensitivity, specificity and efficiency were respectively 72.7, 56.2 and 62.9% for transrectal ultrasound (TRUS); 80, 56.2 and 65.3% for CDU and 88.8, 54.5 and 68% for CDU after Levovist s injection; 66.5, 72.6 and 65.1% for digito-rectal examination (DRE); 100, 51.4 and 65.4% for total PSA; and 100, 88.8 and 94.3% for PSA free/total. In the 16 patients with prostate carcinoma, the sensitivity of CDU after Levovist s was 92.3, 66% for both DRE and TRUS, and 80% for DRE plus TRUS. Conclusions: Considering the cost and the results obtained (high sensitivity and low specificity), a routine use of Levovist s does not seem indicated in patients undergoing prostatic biopsy. An exception may be represented by patients with both negative DRE and TRUS.
Introduction
Many reports have shown that sextant biopsies 1 do not detect all clinically significant prostate cancers (PCa), and a large number of investigators have modified the standard sextant biopsy scheme, increasing the number of samples especially in the peripheral portion of the gland, with an increase of detection rate for PCa (25 vs 40%). 2 The drawbacks of transrectal ultrasound (TRUS) in detecting PCa (high sensitivity and low specificity) have been a great spur to improve the TRUS technique. Sonographic diagnosis has been enriched in recent years by the introduction of tridimensional images and by the use of contrast media, which allows better characterization of intraparenchymal vascularization. 3 Echoamplifiers are composed of inert molecules of galactose, which are administered parenterally and permit an improvement of color-and power-Doppler signal especially in the organs with a slow blood flow, as they can visualize even the smallest vessels formatted around a tumor. 4 We report on our experience with the use of Levovist s (Schering) in the diagnosis of PCa to evaluate whether the adjunct of an ultrasound contrast medium improves the accuracy of TRUS.
Materials and methods
Between July 2000 and June 2001 in 34 patients (age range 53-74 y; median age 65 y), who were scheduled to undergo a trans-perineal prostate biopsy, we carried out a color-Doppler ultrasound (CDU) and power-Doppler ultrasound (PDU) of the prostate using a 7 MHz biplanar transrectal probe (GE Logiq 500 PRO). The power and color signals were evaluated before and after an i.v. injection of 4 g of an ultrasound contrast medium (Levovist s ) in 8 ml of saline administered in 60 s (Figure 1 ) at the same gain and lower pulse repetition frequency (PRF) with a velocity scale of 2.2 cm/s. Any focal and asymmetric increase of vascularization in the prostate peripheral region within 5 min after the injection of Levovist s was considered as an abnormal finding.
Prostate biopsies were carried out using automatic trucut 18 G needles for local anesthesia with 10 mg of lidocain. We performed the extended biopsy scheme of Ravery et al: 5 three cores in each lobe (base, median portion and apex), three cores on the left and right lateral margin of the gland and two additional cores on the transition zone. In the areas where a marked increase in vascularization after the Levovist s injection was visible, further bioptic samples were taken.
Results
Patients' data are summarized in Table 1 . In all, 19 patients had a positive digito-rectal examination (DRE); in one case the PSA was o4 ng/ml, in 19 it ranged between 4 and 10 ng/ml and in 14 cases between 10 and 25.5 ng/ml; TRUS showed a peripheral hypoechoic zone in 24 cases. Transrectal CDU and PDU demonstrated a marked increase in the color and power signal in correspondence of the peripheral region of the prostate In 16/34 patients (47%) PCa was diagnosed; in 16 cases (47%) bioptic samples revealed a benign prostatic hyperplasia and in the remaining two cases a prostatitis was diagnosed. In patients with PCa, DRE was inconclusive in six patients, total PSA ranged between 5.2 and 25.5 ng/ml and PSA free/total between 10 and 19%; TRUS was negative in six patients, the basic CDU and PDU in four and after Levovist s in two (Table 2 ). Only one case required a bioptic sample on a hypervascularized area (which was subsequently negative on the histologic examination), while in the other cases an increase of the color signal in the peripheral region of the gland, which would normally be submitted for extended biopsy, was evident.
In the 6/16 patients with normal DRE or TRUS, CDU before and after Levovist s was negative in four and two cases, respectively. In the two patients, in which DRE and TRUS were both normal, CDU before and after Levovist s was negative in two and one case, respectively.
The overall diagnostic sensitivity, specificity and efficiency in the 34 patients who underwent prostate biopsy were respectively 72. 
Discussion
TRUS is not considered to be a method of screening for PCa as a result of its high cost and low specificity: currently it is used by many authors for prostate biopsy and for the evaluation of some clinical parameters (PSA density, PSA transition zone).
A number of works have been published relating to the use of ultrasound contrast medium in the diagnosis of PCa. [4] [5] [6] [7] Kelly et al 7 reported a sensitivity for TRUS and CDU, respectively, of 96 and 87%, with only one out of 158 cases of adenocarcinoma not visible with a standard TRUS. Newman et al 8 reported a sensitivity and specificity for malignancies of 49 and 93% emphasizing the necessity of a biopsy, even in patients with a negative CDU. Patel and Rickards, 9 based on the results of 274 biopsies, considered the CDU to be relatively useful in the diagnosis of neoplastic pathologies. Borges et al, 10 on the other hand, were the first to report on the use of Levovist s in 18 patients with suspected PCa, revealing a sensitivity of 85 against 77% for the TRUS; they quoted, in addition, six patients with normal TRUS and a positive contrast-enhancement in three of them (all these patients harbored a neoplasm). Recently, Halpern et al 11 have demonstrated that targeted biopsy performed on the basis of high-frequency color or Doppler findings will miss a substantial number of cancers detected with a modified sextant biopsy approach with laterally directed cores.
The use of intermittent ultrasound images improves the color signal created by the contrast medium. A longer interval between each frame allows a more detailed visualization of the microvessels. A number of computerized programs have recently been developed for the elaboration of color signals in 3-D echography, which seem to allow a better sensitivity and an improved reproduction. [12] [13] [14] [15] [16] [17] In our experience, only in one patient with PCa, DRE and TRUS within normal limits and an increased total PSA, the CDU after Levovist s revealed a better sensitivity compared to the standard sonography; in all the other patients, DRE and/or TRUS, in addition to total and free/total PSA, were always positive.
In conclusion, considering its high cost (223.16 euro per vial) and the poor results in terms of high sensitivity Moreover, the employment of an extended scheme of prostate biopsy improves the detection rate for cancer and it also allows a fairly accurate local staging of the disease in patients with early PCa (T1c). 18, 19 A similar diagnostic accuracy cannot be supported by TRUS or CDU and PDU.
